Acute Coronary Syndrome: Secondary Prevention | Disease Landscape & Forecast | G7 | 2025
Acute coronary syndrome (ACS) encompasses acute ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, and unstable angina. ACS is a significant cause of morbidity and mortality in developed countries. The therapy market is divided into the acute hospital setting and the post-hospital secondary prevention setting. This report focuses on the 12-month post-hospital secondary prevention market. The post-ACS market is currently dominated by oral antiplatelet agents, statins, beta blockers, and angiotensin pathway modulators. Despite optimal therapy, the risk of recurrent ischemic events in post-ACS patients remains high. The identification of new risk factors and potential targets has led to new opportunities for pharmaceutical companies to develop drugs that address the limitations of current treatments. Indeed, the forecast period is expected to see the launch of novel lipid-lowering, antithrombotic, and anti-inflammatory agents aimed at further reducing the risk of cardiovascular events and disease progression.
Questions answered
- What factors will drive and constrain the growth of the ACS secondary prevention market?
- What is the commercial potential of Lp(a) inhibitors (pelacarsen, olpasiran, and lepodisiran), emerging PCSK9 inhibitors (inclisiran [Leqvio], enlicitide), and the FXIa inhibitor milvexian?
- How do leaders in the field of ACS management rate the novel therapies targeting Lp(a) and inflammation?
- To which patients do physicians prescribe the PCSK9 inhibitors? What is their opinion on the future of this class in the secondary prevention of ACS?
Geography
United States, EU5, Japan
Primary research
- Country-specific interviews with thought-leading cardiologists
- Survey data collected for this and other Clarivate research
Epidemiology
12-month diagnosed prevalent cases of ACS by country and subtype
Forecast
10-year, annualized, drug-level sales and patient share of key ACS secondary prevention therapies through 2034, segmented by brands / generics
Drug treatments
Coverage of key current and late-phase emerging therapies
Product description
Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:
- Optimize your long-term disease and development strategy.
- Quantify market potential for your pipeline assets and those of your competitors.
- Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
- Gauge the commercial outlook and impact of key market events.
